Drug intelligence / Profile preview

Ex-vivo expanded effector cells-Dartmouth-Hitchcock Medical Center-multiple myeloma

Development stage: Unknown
Lead developer: Dartmouth Hitchcock Medical Center
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Tumor-Infiltrating Lymphocytes (TILs) → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

Ex-vivo expanded effector cells-Dartmouth-Hitchcock Medical Center-multiple myeloma refers to an autologous adoptive cellular immunotherapy investigated by Dartmouth-Hitchcock Medical Center for the treatment of multiple myeloma. The therapy involves the ex-vivo expansion and activation of a patient's own cytotoxic T cells (effector cells) to enhance their anti-tumor activity. These expanded cells are re-infused into the patient following autologous peripheral blood stem cell transplantation (APBSCT), a timing intended to optimize immune reconstitution and induce an effector cell-versus-myeloma effect. In clinical study protocols, this cell therapy was evaluated in combination with Interleukin-2 (IL-2) and Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) to support the survival, proliferation, and functional activity of the infused T cells.

Other names: Ex-vivo expanded effector cellsEx-vivo expanded cytotoxic T cellsAdoptive cellular immunotherapy

Targets

NKG2DL (NKG2D ligand family)MM-TAAs (Multiple myeloma-associated tumor-associated antigens presented on MHC molecules)

Beyond the preview

Go deeper on Ex-vivo expanded effector cells-Dartmouth-Hitchcock Medical Center-multiple myeloma.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ex-vivo expanded effector cells-Dartmouth-Hitchcock Medical Center-multiple myeloma.

Explore the full profile